OBJECTIVES: The goal of this study was to determine if low to moderate doses of anthracycline-based chemotherapy (Anth-bC) are associated with subclinical cardiovascular (CV) injury. BACKGROUND: Cancer survivors who receive Anth-bC experience premature CV events. It is unknown whether low to moderate doses of anthracyclines promote early subclinical CV disease manifested by deteriorations in left ventricular ejection fraction (LVEF) or increases in aortic stiffness, or if these doses are associated with changes in quality of life (QOL). METHODS: In 53 men and women with breast cancer, leukemia, or lymphoma, we assessed left ventricular volumes, LVEF, circumferential strain, aortic pulse wave velocity, late gadolinium enhancement, serum B-type natriuretic peptide, troponin I, and the impact of treatment on QOL before and 1, 3, and 6 months after receipt of Anth-bC. RESULTS: Participants averaged 50 ± 2 (range 19 to 80) years in age, 58% were women, 17% were black, and they each received a range of 50 to 375 mg/m(2) of doxorubicin-equivalent chemotherapy. Left ventricular end-systolic volume (48 ± 3 ml to 54 ± 3 ml; p = 0.02), left ventricular strain (-17.7 ± 0.4 to -15.1 ± 0.4; p = 0.0003), pulse wave velocity (6.7 ± 0.5 m/s to 10.1 ± 1 m/s; p = 0.0006), and QOL deterioration (15.4 ± 3.3 to 28.5 ± 3.9; p = 0.008) increased, whereas LVEF (58 ± 1% to 53 ± 1%; p = 0.0002) decreased within 6 months after low to moderate doses of Anth-bC. All findings persisted after accounting for age, gender, race (white/black), doxorubicin-equivalent dose, doxorubicin administration technique, comorbidities associated with CV events, and cancer diagnosis (p = 0.02 to 0.0001 for all). There were no new late gadolinium enhancement findings after 6 months. CONCLUSIONS: In these study patients, low to moderate doses of Anth-bC were associated with the early development of subclinical abnormalities of cardiac and vascular function that in other populations are associated with the future occurrence of CV events.
OBJECTIVES: The goal of this study was to determine if low to moderate doses of anthracycline-based chemotherapy (Anth-bC) are associated with subclinical cardiovascular (CV) injury. BACKGROUND:Cancer survivors who receive Anth-bC experience premature CV events. It is unknown whether low to moderate doses of anthracyclines promote early subclinical CV disease manifested by deteriorations in left ventricular ejection fraction (LVEF) or increases in aortic stiffness, or if these doses are associated with changes in quality of life (QOL). METHODS: In 53 men and women with breast cancer, leukemia, or lymphoma, we assessed left ventricular volumes, LVEF, circumferential strain, aortic pulse wave velocity, late gadolinium enhancement, serum B-type natriuretic peptide, troponin I, and the impact of treatment on QOL before and 1, 3, and 6 months after receipt of Anth-bC. RESULTS:Participants averaged 50 ± 2 (range 19 to 80) years in age, 58% were women, 17% were black, and they each received a range of 50 to 375 mg/m(2) of doxorubicin-equivalent chemotherapy. Left ventricular end-systolic volume (48 ± 3 ml to 54 ± 3 ml; p = 0.02), left ventricular strain (-17.7 ± 0.4 to -15.1 ± 0.4; p = 0.0003), pulse wave velocity (6.7 ± 0.5 m/s to 10.1 ± 1 m/s; p = 0.0006), and QOL deterioration (15.4 ± 3.3 to 28.5 ± 3.9; p = 0.008) increased, whereas LVEF (58 ± 1% to 53 ± 1%; p = 0.0002) decreased within 6 months after low to moderate doses of Anth-bC. All findings persisted after accounting for age, gender, race (white/black), doxorubicin-equivalent dose, doxorubicin administration technique, comorbidities associated with CV events, and cancer diagnosis (p = 0.02 to 0.0001 for all). There were no new late gadolinium enhancement findings after 6 months. CONCLUSIONS: In these study patients, low to moderate doses of Anth-bC were associated with the early development of subclinical abnormalities of cardiac and vascular function that in other populations are associated with the future occurrence of CV events.
Authors: M A Quiñones; B H Greenberg; H A Kopelen; C Koilpillai; M C Limacher; D M Shindler; B J Shelton; D H Weiner Journal: J Am Coll Cardiol Date: 2000-04 Impact factor: 24.094
Authors: Thomas S Rector; Peter E Carson; Inder S Anand; John J McMurray; Michael R Zile; Robert S McKelvie; Michel Komajda; Michael Kuskowski; Barry M Massie Journal: Circ Heart Fail Date: 2012-01-20 Impact factor: 8.790
Authors: Thomas Eschenhagen; Thomas Force; Michael S Ewer; Gilles W de Keulenaer; Thomas M Suter; Stefan D Anker; Metin Avkiran; Evandro de Azambuja; Jean-Luc Balligand; Dirk L Brutsaert; Gianluigi Condorelli; Arne Hansen; Stephane Heymans; Joseph A Hill; Emilio Hirsch; Denise Hilfiker-Kleiner; Stefan Janssens; Steven de Jong; Gitte Neubauer; Burkert Pieske; Piotr Ponikowski; Munir Pirmohamed; Mathias Rauchhaus; Douglas Sawyer; Peter H Sugden; Johann Wojta; Faiez Zannad; Ajay M Shah Journal: Eur J Heart Fail Date: 2011-01 Impact factor: 15.534
Authors: Chung-Lieh Hung; Anil Verma; Hajime Uno; Sung-Hee Shin; Mikhail Bourgoun; Amira H Hassanein; John J McMurray; Eric J Velazquez; Lars Kober; Marc A Pfeffer; Scott D Solomon Journal: J Am Coll Cardiol Date: 2010-11-23 Impact factor: 24.094
Authors: Jennifer H Jordan; Bunyapon Sukpraphrute; Giselle C Meléndez; Marie-Pierre Jolly; Ralph B D'Agostino; W Gregory Hundley Journal: Circulation Date: 2017-06-20 Impact factor: 29.690
Authors: Vinita Dhir; Andrew T Yan; Rosane Nisenbaum; Joanna Sloninko; Kim A Connelly; Joseph Barfett; Rashida Haq; Anish Kirpalani; Kelvin K W Chan; Teresa M Petrella; Christine Brezden-Masley Journal: Int J Cardiovasc Imaging Date: 2019-06-13 Impact factor: 2.357